We demonstrate significant NECTIN4-CAR T anti-tumor activity in both EV-naïve and EV-resistant settings, and identify a strategy to turn low-expressing tumors into higher-expressing tumors, thereby making them become more susceptible to NECTIN4-CAR T therapy. The gene discussed is NECTIN4; the disease is neoplasm.